Pharmaceutical & Biotech
News and Insights
21st Century Cures Act is passed by the US House
The 21st Century Cures Act, which will provide more funding to the FDA and NIH, was approved with a 344 to 77 vote. People who ...
AbbVie's Hepatitis C treatment has 100% cure rate
AbbVie unveiled some new data that shows that its Viekira Pak, which combines Vikirax and Exviera, delivered a 100% continued response rate in genotype 1b ...
Biotech companies topping Fortune’s fastest-growing pharma list
Fortune 500's fastest-growing pharma list is out and surprisingly only one big pharma company has made the top five. 1) Gilead with a 5-year annual ...
Actavis is now Allergan
Following its November buyout, Actavis has announced that it will now be known as Allergan. The company has changed its ticker symbol on the New ...
Big Pharma Advertising
The most common mode of advertising for Big Pharma companies remains to be television. With the increased presence of social media, digital and mobile advertising, ...
IMS report: Cancer drug spending increases to $100B
New IMS numbers show that global spending on cancer therapies have increased $75 billion in just the last 5 years with a 10.3% increase in ...
Mylan rejects Teva’s offer
Mylan has rejected a $40 billion offer from Teva to become the industry's biggest generic drug company. The reasoning behind the rejection was Mylan felt ...
Good news for GW Pharmaceutical’s epilepsy drug
New data from a Phase III study of GW Pharmaceuticals' in-development epilepsy drug shows a reduction the rates of seizures by more than 50%. The ...
Teva to buy Auspex
Teva announced that they have entered into a definitive merger agreement with Auspex Pharmaceuticals. Teva will pay $101 per share, or about $3.2 billion for ...
New Alzheimer's R&D project
With the number of people with dementia expected to triple by 2050, several industry giants are investing in a $100 million effort to find effective ...
- page 1 of 3 -